Support program for people newly diagnosed with retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This study is testing a new way to support people who have just been told they have retinitis pigmentosa (RP) at the Quinze-Vingts hospital in Paris. It aims to help you understand your diagnosis and get the care you need.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with retinitis pigmentosa (RP) at the Quinze-Vingts Rare Eye Disease Center since the study started.
- You are between 18 and 65 years old.
- You speak French.
- You have a phone number and live in France.
- You are not pregnant.
- You have not been in another clinical trial in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.